cliffwatch

sugammadex sodium · Msd Sub Merck · NDA 022225

Bridion

Earliest generic entry, as listed · earliest of 2 marketed strengths
12 Jun 2028

Blocked by exclusivity: PED.

Listed patents · 0 unexpired

No unexpired patents listed.

Exclusivities · 2 unexpired

PEDpediatric (6 months added)12 Jun 2028
NPPnew patient population12 Dec 2027

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

  • 25 Oct 2026Generic approved · 022225-001
  • 25 Oct 2026Generic approved · 022225-001
  • 25 Oct 2026Generic approved · 022225-001
  • 25 Oct 2026Generic approved · 022225-001
  • 25 Oct 2026Generic approved · 022225-001
  • 25 Oct 2026Generic approved · 022225-001
  • 25 Oct 2026Generic approved · 022225-001
  • 25 Oct 2026Generic approved · 022225-001
  • 25 Oct 2026Generic approved · 022225-001
  • 25 Oct 2026Generic approved · 022225-001
  • 25 Oct 2026Generic approved · 022225-001
  • 25 Oct 2026Generic approved · 022225-001
  • 25 Oct 2026Generic approved · 022225-001
  • 25 Oct 2026Generic approved · 022225-001
  • 25 Oct 2026Generic approved · 022225-001
  • 25 Oct 2026Generic approved · 022225-001
  • 25 Oct 2026Generic approved · 022225-001

Products covered · 2

NDA · productFormStrengthListed expiry
022225 · 001 · RLDsolution, intravenousEQ 500MG BASE/5ML (EQ 100MG BASE/ML)12 Jun 2028
022225 · 002 · RLDsolution, intravenousEQ 200MG BASE/2ML (EQ 100MG BASE/ML)12 Jun 2028
Expired or delisted (2)
  • US RE44733 · — · 27 Jul 2026
  • US RE44733 · substance, product, use U-1794 · 27 Jan 2026